

Humber Area Prescribing Committee

Date / Time	3 rd August 2022
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No – to contact Dr Pothina to confirm happy with decisions and recommendations

Attendance	Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR) Prof A Morice – Professor of Respiratory Medicine, Chair of D&TC HUTH Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Andrew Karvot – Advanced Clinical and Northern Lincolnshire - Interface Pharmacist (AK) Marian Opoku-Fofie – Deputy Chief Pharmacist – Humber Teaching NHS Foundation Trust (MOF) Weeliat Chong, Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC) Joanne Goode – Chief Pharmacist – HUTH (JG) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Simon Priestley- Chief Pharmacist, NLAG (SP) Dr Anupam Sinha- NEL GP Prescribing Lead (AS)
-------------------	---

Apologies	Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Dr Narayana Pothina- Consultant in adult medicine – NLAG Emma Baggaley, Head of Medicines Service, CHCP (EB)
------------------	---

Agenda Number	Item	Discussion	Action	Lead	Due Date
2022.08.01	Apologies	Noted above			
2022.08.02	Declarations of interest	None			
2022.08.03	Minutes of previous meeting	Accepted as true record			
2022.08.04	Action Tracker	<ul style="list-style-type: none"> • Stakeholder mapping and engagement- JM and LB have updated mapping and updated briefing. JM and LB to meet outside and circulate updated briefing to mapped stakeholders • Ratification of APC guidelines/SCFs- AK uploaded unlicensed medicine guideline to new Humber APC website. Welcoming comments on how to improve website • Outstanding actions from NLAPC- JM has emailed Mr Gandhi about overactive bladder pathway with no response, will contact again along with secretary. SR out forward that the guideline should be accepted unless Mr Gandhi objects. As this guidance initiated from NLAG to approve for use in NEL/NL and begin the process of having the guideline in place. • Traffic Light Status- Formulary updated. JM pointed out that both formularies will need to be updated as we progress with the swap from HERPC to HAPC website. • Work plans- Standing item on agenda • Guidelines- JM updating headache guidance will send to AK when ready to upload • Joint Formulary- Chapter 4 currently in progress of being transferred onto net formulary site 	<p>JM/LB to discuss updated briefing and circulate</p> <p>Action complete</p> <p>For IMOC for info and AK to arrange upload of guidance on NLG webpage and on APC webpage. JM to chase Mr Gandhi</p> <p>Action complete</p> <p>Action complete JM to finalise document and send to AK</p> <p>Complete transfer to net formulary and remove chapter 4 from HERPC formulary</p>	<p>JM/LB</p> <p>AK</p> <p>JM/AK</p> <p>JM/LS/AK</p> <p>JM/AK</p> <p>JM/AK/LS</p>	<p>9/22</p> <p>9/22</p> <p>9/22</p> <p>9/22</p>

2022.08.05	Outstanding actions from NLAPC	<ul style="list-style-type: none"> • <i>Mycophenolate</i>- Awaiting funding • <i>Inclisiran</i>- Ongoing- JM shared document with NP and will share with consultant in charge of lipid service. Put toward guideline group in future. • <i>ADHD Shared care (NL)</i> - Guideline has been approved, funding is still awaiting approval. WC raised that Hull and East Riding of Yorkshire guidelines are out of date. Discussed that a larger project would be best to have a regional shared care but it is a large project with limited time for each area. Suggested that the RMOG be adapted to the current out of date guidance while the NL and North East Lincolnshire remain as they are still in date then product an overall document by January 2023. • <i>Azathioprine shared care for gastro</i>- Shared cared accepted, awaiting clarification around funding. • <i>Riluzole shared care</i>- Shared care approved, awaiting confirmation of funding in both NEL/NL as want to launch when funding available at both Places • <i>Modafinil</i>- Shared care approved, awaiting confirmation of funding in both NEL/NL as want to launch when funding available at both Places • <i>Atomoxetine liquid</i>- in conjunction with ADHD shared care • <i>Overactive bladder in female patients</i>- complete on this tracker. On Humber APC tracker now • <i>Prescribing in gestational diabetes</i>- Discussed at business meeting and currently being looked at standardisation of practice across Northern Lincolnshire places • <i>Prescription requests in secondary care</i>- AK received documents from JM for HUTH and shared relevant policies from NLAG. To upload relevant policies for info on APC website and JM/AK to review HUTH document and include NLAG info in similar summary document • <i>Appropriate prescribing of specialist infant formulae</i>- AK awaiting on paediatric dietitian from NLAG but no correspondence. Raise action with paediatric 	<p>Update next time Add to next guideline group with HUTH lipid guidance JM to review RMOG guidance and adapt onto template – to send to WC/MOF for circulation around Humber teams and to circulate in community paediatrics. To update next time</p> <p>Update next time</p> <p>Update next time</p> <p>See discussions above. Action complete</p> <p>JM/AK to review documents and prepare a summary for APC</p> <p>Share with paediatric dietitian- produce</p>	<p>RS JM/LS</p> <p>JM WC/MOF</p> <p>RS</p> <p>RS</p> <p>RS</p> <p>AK</p> <p>JM/AK</p>	<p>9/22 9/22</p> <p>9/22 9/22</p> <p>9/22</p> <p>9/22</p> <p>9/22</p> <p>11/22</p>
------------	--------------------------------	--	---	---	--

		dietitian's across area and correspond with NLAG to then produce a joint document.	document/look at merge		
2022.08.06	Outstanding actions from HERPC	<ul style="list-style-type: none"> • <i>Rheumatology to prepare pathway with rituximab without MTX- still with rheumatology as continuously updating. Review date moved to sept 22</i> • <i>KMc and JM to work with CCG to approve MS guideline- Sent to pathway review group but groups have realigned. JM to contact Gary to check if pathway groups are still going or changing to something else</i> • <i>JM to meet with business manager in ophthalmology to discuss drafting HUTH pathway and work towards commissioning- JM emailed multiple times with no reply. Escalate through HUTH D&T.</i> • <i>Diabetes guideline – JM to review diabetes guideline when NICE publish and discuss with Diabetologists- On agenda</i> • <i>JM to confirm prescribing arrangements with specialist team- JM to email</i> • <i>JM to update with alternative H2 receptor antagonist and review plan for renal repatriation- JM updated and further review of renal repatriation</i> 	<p>JM to contact Dr Ogumbambi</p> <p>JM to contact Gary Hepworth</p> <p>To discuss at HUTH D&TC</p> <p>See agenda section</p> <p>JM to contact Mr Phillips</p> <p>JM to meet with renal teams</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>9/22</p> <p>10/22</p> <p>9/22</p> <p>9/22</p> <p>9/22</p>
2022.08.07	Traffic Light Status	<p>July 2022- HUTH D&T: Saciztuzumab govitecan- proposed as RED Bertolastat- proposed as RED Mogamulizumab- Proposed as RED Tucatinib, capecitabine, trastuzumab- Proposed as RED</p> <p>NLAG M&T: Sterile talcum powder- proposed as RED Mydraine® Tropicamide, phenylephrine and lidocaine intracameral injection- Proposed as RED</p>	Update formulary/red list	LS	9/22
2022.08.08	Feedback from Integrated Medicines Optimisation Committee	<p>East Riding place- New place director Simon Cox Hull Place- new director Erica Daly Integrated optimisation committee first meeting 20th July</p>	Noted		
2022.08.09	Work plans	<p>a) Joint formulary alignment b) Shared care frameworks c) Guidelines</p>	Noted		

2022.08.10	Ratification of guidelines and SCFs	<p>a) LVSD medicines management pathway- updated since circulation, rewording of carvedilol dose to be clearer.</p> <p>b) Type 2 diabetes (Hull and ERY) – updated guidance from HERPC action tracker including reflection of new NICE update. However, the diabetes team would like to work to a hybrid model (NICE and EASD/ADA consensus guidance). The current NEL/NL guidance is based on the EASD/ADA guidance. The main difference would be place in therapy for GLP-1 inhibitors being used 2nd line after first line therapy with metformin plus SGLT2 inhibitor. NICE did not complete a full review at last review and did not recommend GLP-1 Ix for patient with diabetes and cardiovascular disease. The timeline for the full medicines update from NICE is TBC. KMc raised that NYY APC are also currently reviewing their diabetes guidance have looked at costing for GLP-1 inhibitors as second line therapy in this. This costing is likely to be similar if not higher for Hull and ERY.</p> <p>c) Acute Diabetic Foot Emergency Guidance for Primary Care Practitioners</p>	<p>Approved – for information at IMOC</p> <p>Recommended- for discussion at IMOC</p> <p>For next meeting</p>	<p>RS</p> <p>RS</p>	
2022.08.11	Ratification of joint formulary	Chapter 2- Due to time restraints will be reviewed next meeting	For next meeting		
2022.08.12	RTDC Updates	<p>a) May 2022</p> <p>b) June 2022</p>	For next meeting		
2022.08.13	Minutes from subcommittees	<p>a) Joint formulary subcommittee (June 2022)</p> <p>b) Guideline subcommittee (April 2022)</p>	Noted		
2022.08.14	Additional Minutes for information	<p>a) HUTH D&TC (None)</p> <p>b) HFT DTG (May 2022)</p> <p>c) NLAG M&T (June 2022)</p> <p>d) NYY APC (May 2022)</p>	Noted		
2022.08.15	AOB	<p>a) Buprenorphine leaflet- reviewed item for Hull and ERY currently. To review with Palliative care team on</p> <p>b) Palliative care- Reviewed item, this is Hull and ERY guidance and is what is also used on community drug charts for administration of these medicines.</p> <p>c) PPI information- RS presented this PIL comments on inclusion of why the acid is produced, removal of non-formulary medicines, how to use PPI and to remove PPI treats reflux.</p>	<p>Approved – for info at IMOC</p> <p>Approved – for info at IMOC</p> <p>Update and approved for info at IMOC</p>		

2022.08.16	Date of next meeting	7 th September 2022 13:00-15:00			
-------------------	-----------------------------	--	--	--	--